|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
inhibits viral replication
inhibits viral RNA polymerase
|
|
gptkbp:age
|
12 years and older
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
gptkb:U._S._Food_and_Drug_Administration
|
|
gptkbp:availability
|
available in pharmacies
|
|
gptkbp:clinical_trial
|
high
Phase III
single-dose treatment
|
|
gptkbp:contraindication
|
hypersensitivity to baloxavir
|
|
gptkbp:developed_by
|
gptkb:Shionogi
gptkb:Shionogi_&_Co.
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
1 dose
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Xofluza
|
|
gptkbp:indication
|
acute uncomplicated influenza
|
|
gptkbp:ingredients
|
gptkb:baloxavir_marboxil
C19 H18 F2 N2 O4 S
|
|
gptkbp:interacts_with
|
may interact with certain vaccines
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_compared_to
|
compared to oseltamivir
compared to zanamivir
|
|
gptkbp:is_effective_against
|
reduces duration of flu symptoms
|
|
gptkbp:is_used_for
|
treatment of influenza
|
|
gptkbp:lifespan
|
approximately 19 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Shionogi_&_Co.,_Ltd.
|
|
gptkbp:marketed_as
|
gptkb:United_States
Xofluza brand name
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:price
|
varies by location
|
|
gptkbp:provides_information_on
|
CDC recommends use
included in flu treatment guidelines
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research
|
ongoing studies for effectiveness
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
vomiting
diarrhea
insomnia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:target_audience
|
adults and children
|
|
gptkbp:traded_on
|
gptkb:Xofluza
|
|
gptkbp:treatment
|
within 48 hours of symptom onset
|
|
gptkbp:weight
|
392.42 g/mol
|
|
gptkbp:bfsParent
|
gptkb:baloxavir_marboxil
|
|
gptkbp:bfsLayer
|
5
|